ergoline and Chronic-Disease

ergoline has been researched along with Chronic-Disease* in 14 studies

Reviews

1 review(s) available for ergoline and Chronic-Disease

ArticleYear
Medication-induced headache: overview and systematic review of therapeutic approaches.
    The Annals of pharmacotherapy, 1999, Volume: 33, Issue:1

    To review medication-induced headache (MIH) through a systematic evaluation of the literature regarding the pharmacologic management of this condition.. To identify and evaluate all pharmacologic interventions for MIH, we conducted a qualitative systematic review of the English-language literature from 1966 to June 1998 using MEDLINE. The following search terms were used: chronic daily headache, transformed migraine, analgesic withdrawal headache, analgesic rebound headache, drug-associated headache, medication-induced headache, detoxification, and dihydroergotamine. In addition, a review of the references from relevant literature was also conducted to collect reports not identified in the MEDLINE search.. Numerous therapies for acute management of MIH have been evaluated, although no rigorously conducted clinical trials were identified. Therapies evaluated include abrupt withdrawal of analgesics, initiation of dihydroergotamine, nonsteroidal antiinflammatory agents, methylergonovine, dihydroergotamine, sumatriptan, amitriptyline, dexamethasone, piracetam, prothipendyl, and valproate. Epidemiology, diagnosis, clinical features, pathophysiology, and long-term prognosis of therapy are discussed and therapeutic guidelines are offered.. MIH is an underrecognized and difficult condition affecting headache-prone patients. The published literature concerning treatment of patients with MIH is scant and of poor quality, making it difficult for clinicians to decide on appropriate therapy. Recognition and treatment of MIH may lead to a long-term improvement in headache relief for many patients. It appears that complete withdrawal of the medications being overused is required for favorable long-term results.

    Topics: Amitriptyline; Analgesics; Anti-Inflammatory Agents; Chronic Disease; Ergolines; Headache; Humans; MEDLINE; Piracetam; Randomized Controlled Trials as Topic; Substance Withdrawal Syndrome; Sumatriptan; Thiazines; Valproic Acid

1999

Trials

4 trial(s) available for ergoline and Chronic-Disease

ArticleYear
[The role of nicergoline in the symptomatic treatment of arterial hypertension and chronic cerebrovascular insufficiency. A study on 359 observations (author's transl)].
    Arzneimittel-Forschung, 1979, Volume: 29, Issue:8a

    An examination was carried out on the efficacy of 10-methoxy-1,6-diemethyl-ergoline-8 beta-methanol-(5-bromonicotinate) (nicergoline, Sermion) on the symptoms of functional side effects of arterial hypertension and chronic circulatory insufficiency as regards the psychomotoric activity and the relational activity; 359 patients suffering from crebrovascular insufficiency were included in the study. The compound was applied in a daily dose of 10 mg i. m. for 5 days and then in a daily dose of 15 mg orally for 1 month. In the entire symptom complex of cerebro-vascular insufficiency a positive effect of nicergoline could be observed; the results of all clinical criteria and their therapeutic relevance are discussed.

    Topics: Adult; Aged; Cerebrovascular Disorders; Chronic Disease; Clinical Trials as Topic; Ergolines; Female; Humans; Hypertension; Male; Middle Aged; Nicergoline

1979
Clinical evaluation of (-)eburnamonine in comparison with nicergoline in patients suffering from chronic brain ischemia.
    European neurology, 1978, Volume: 17 Suppl 1

    The activity of (-)eburnamonine, a substance acting on the cerebral circulation and metabolism, was compared with that of nicergoline in a double-blind study carried out on a group of 28 patients (16 males and 12 females), suffering from established chronic brain ischemia. The treatment consisted of the administration for the first 5 days of 80 mg/day and for the following days of 60 mg/day of (-)eburnamonine, in 14 subjects. Nicergoline was administered to the other 14 subjects: 20 mg/day for the first 5 days and then 15 mg/day. The treatment was protracted for at least 20 days. (-)Eburnamonine appeared to influence some symptoms more rapidly and significantly than nicergoline. After 20 days of treatment the overall improvement obtained with (-)eburnamonine was 31 and 18% with nicergoline. No side effects or impairment of the biochemical tests appeared during either treatment.

    Topics: Aged; Brain; Brain Ischemia; Cerebrovascular Circulation; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Drug Evaluation; Ergolines; Female; Humans; Male; Nicergoline; Placebos; Vasodilator Agents; Vinca Alkaloids

1978
Effects of lergotrile on schizophrenia & drug induced parkinsonism.
    Communications in psychopharmacology, 1977, Volume: 1, Issue:5

    Topics: Acetonitriles; Adult; Antiparkinson Agents; Antipsychotic Agents; Chronic Disease; Clinical Trials as Topic; Double-Blind Method; Drug Therapy, Combination; Ergolines; Female; Fluphenazine; Humans; Middle Aged; Parkinson Disease, Secondary; Prolactin; Schizophrenia

1977
[Comparative evaluation of the new antiserotonin preparations, sandomigran and lizenil, in treating patients suffering from migraine].
    Zhurnal eksperimental'noi i klinicheskoi meditsiny, 1976, Volume: 16, Issue:5

    Topics: Adult; Cerebrovascular Circulation; Chronic Disease; Clinical Trials as Topic; Czechoslovakia; Drug Evaluation; Ergolines; Female; Humans; Male; Middle Aged; Migraine Disorders; Pizotyline; Serotonin Antagonists; Sweden; Thiophenes; Urea

1976

Other Studies

9 other study(ies) available for ergoline and Chronic-Disease

ArticleYear
Chronic anemia as first clinical manifestation of a prolactin-secreting pituitary macroadenoma in a male patient.
    The American journal of medicine, 2011, Volume: 124, Issue:6

    Topics: Anemia; Antineoplastic Agents; Biomarkers, Tumor; Cabergoline; Chronic Disease; Dopamine Agonists; Drug Therapy, Combination; Early Detection of Cancer; Ergolines; Hematocrit; Hemoglobins; Hormone Replacement Therapy; Humans; Hydrocortisone; Hypogonadism; Hypopituitarism; Magnetic Resonance Imaging; Male; Middle Aged; Pituitary Neoplasms; Prolactin; Prolactinoma; Testosterone; Thyroxine; Treatment Outcome

2011
Increased prevalence of tricuspid regurgitation in patients with prolactinomas chronically treated with cabergoline.
    The Journal of clinical endocrinology and metabolism, 2008, Volume: 93, Issue:10

    Cabergoline, a dopamine receptor-2 agonist used to treat prolactinomas, was associated with increased risk of cardiac valve disease in Parkinson's disease.. Our objective was to evaluate prevalence of cardiac valve regurgitation in cabergoline-treated patients with prolactinomas.. An observational, case-control study was conducted at a university hospital.. Fifty treated patients (44 women and six men) and 50 sex- and age-matched control subjects participated; 20 de novo patients were also studied.. In the treated patients, the last cabergoline dose was 1.3 +/- 1.3 mg/wk (<1 mg/wk in 44%, 1-3 mg/wk in 46%, and >3 mg/wk in 10%). Treatment duration was 12-60 months in 32% and more than 60 months in 68%. The cumulative (milligrams x months of treatment) dose of cabergoline ranged from 32-1938 mg (median 280 mg).. Valve regurgitation was assessed according to the recommendations of the American Society of Echocardiography.. In de novo patients, treated patients, and controls, the prevalence of mild regurgitation of mitral (35, 22, and 12%, P = 0.085), aortic (0, 4, and 2%, P = 0.59), tricuspid (55, 30, and 42%, P = 0.13) or pulmonic (20, 12, and 6%, P = 0.22) valves was similar. Conversely, the prevalence of moderate tricuspid regurgitation was higher in the treated patients (54%) than in de novo patients (0%) and controls (18%, P < 0.0001). Moderate tricuspid regurgitation was more frequent in patients receiving a cumulative dose above the median (72%) than in those receiving a lower dose (36%, P = 0.023). A higher systolic (P = 0.03) and diastolic blood pressure (P < 0.0001) was found in patients with than in those without moderate tricuspid regurgitation.. Moderate tricuspid regurgitation is more frequent in patients taking cabergoline (at higher cumulative doses) than in de novo patients and control subjects, but the clinical significance of this finding has not been established. A complete echocardiographic assessment is indicated in patients treated long term with cabergoline, particularly in those requiring elevated doses.

    Topics: Adult; Antineoplastic Agents; Cabergoline; Case-Control Studies; Chronic Disease; Dose-Response Relationship, Drug; Ergolines; Female; Humans; Male; Middle Aged; Pituitary Neoplasms; Prevalence; Prolactinoma; Time Factors; Tricuspid Valve Insufficiency; Ultrasonography

2008
Clinical and biochemical effects of nicergoline in chronic schizophrenic patients.
    Pharmacopsychiatry, 1986, Volume: 19, Issue:3

    To investigate the potential effect of Nicergoline, an alpha-adrenolytic drug, on negative symptoms in patients suffering from chronic schizophrenia, we administered this compound to 20 male chronic schizophrenics. Patients were previously maintained on long-term neuroleptic (NL) medication. Neuroleptic treatment was discontinued for 12 days, patients were then treated with 30 mg Nicergoline per day. Under NL (A), after 12 days NL-withdrawal (B), after 15 (C) and 30 (D) days Nicergoline treatment clinical ratings (BPRS and AMDP) and stimulation with clonidine (0.002 micrograms/kg body weight) were carried out. Norepinephrine (NE), epinephrine (E), and human growth hormone (HGH) were measured before and after application. Seventeen patients finished the study, 3 dropped out. Some ratings on the AMDP and BPRS scales showed an improvement. However, this improvement was only weak and accompanied by a worsening in other subscores. The withdrawal-induced decrease in NE serum levels continued after 15 days NIC, followed by an increase after 30 days. HGH response to clonidine stimulation was only attenuated after 30 days NIC. Epinephrine, blood pressure and heart rate showed no significant changes throughout the entire study. Our data suggest that NIC in the dosage applied shows no clear and pronounced alpha-2-adrenolytic effects and no specific clinical benefits for chronic schizophrenics. Further investigations are required to evaluate its effect on alpha-1-adrenoceptors.

    Topics: Adult; Chronic Disease; Clonidine; Epinephrine; Ergolines; Growth Hormone; Humans; Male; Middle Aged; Nicergoline; Norepinephrine; Psychiatric Status Rating Scales; Schizophrenia

1986
[Effectiveness of nicergoline in the treatment of chronic cerebrovascular insufficiency (author's transl)].
    Der Nervenarzt, 1980, Volume: 51, Issue:6

    Topics: Aged; Blood Pressure; Brain Ischemia; Cardiac Output; Cerebrovascular Circulation; Chronic Disease; Electroencephalography; Ergolines; Female; Heart Rate; Humans; Male; Middle Aged; Nicergoline

1980
Successful use of bromocriptine in the treatment of a patient with chronic portasystemic encephalopathy.
    The New England journal of medicine, 1977, Apr-07, Volume: 296, Issue:14

    Topics: Bromocriptine; Cerebrovascular Circulation; Chronic Disease; Ergolines; Hepatic Encephalopathy; Humans; Liver Cirrhosis; Male; Middle Aged; Oxygen Consumption

1977
Bromocriptine in encephalopathy.
    The New England journal of medicine, 1977, Aug-25, Volume: 297, Issue:8

    Topics: Bromocriptine; Chronic Disease; Ergolines; Hepatic Encephalopathy; Humans

1977
[Effects of a new vasoactive substance on renal hemodynamics].
    Minerva medica, 1973, Jul-04, Volume: 64, Issue:5

    Topics: Angiotensin II; Bromine; Chronic Disease; Ergolines; Female; Glomerular Filtration Rate; Glomerulonephritis; Hemodynamics; Humans; Injections, Intravenous; Kidney; Male; Nicotinic Acids; Norepinephrine; Regional Blood Flow

1973
[Problems and therapy of chronic hypertensive encephalopathy].
    Die Medizinische Welt, 1973, May-18, Volume: 24, Issue:20

    Topics: Antihypertensive Agents; Cerebrovascular Disorders; Chronic Disease; Ergolines; Female; Humans; Hypertension; Male

1973
[Experience with Lysenyl in allergology].
    Minerva medica, 1972, Sep-01, Volume: 63, Issue:60

    Topics: Adolescent; Adult; Aged; Asthma; Child; Chronic Disease; Conjunctivitis; Eczema; Ergolines; Female; Humans; Hypersensitivity; Male; Meniere Disease; Middle Aged; Migraine Disorders; Rhinitis, Allergic, Seasonal; Urea; Urticaria

1972
chemdatabank.com